{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-25-000068","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.905817+00:00","generated_at":"2026-05-16T13:55:30.075645+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Halozyme elects James Lang to Board of Directors, term through 2027 annual meeting","bullets":["James Lang elected to Halozyme's Board on December 4, 2025.","Mr. Lang's term expires at the 2027 annual meeting of stockholders.","No Board committee assignments initially made.","Compensation follows standard non-employee director program as described in the 2025 proxy.","No related party transactions or arrangements exist with Mr. Lang."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-25-000068","json":"https://secwatch.observer/filing/0001159036-25-000068.json","markdown":"https://secwatch.observer/filing/0001159036-25-000068.md","text":"https://secwatch.observer/filing/0001159036-25-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000068/0001159036-25-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000068/halo-20251204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:55:30.075645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}